{
  "main_header": {
    "sid": 683231,
    "name": "Zenotech Lab.",
    "stock_name": "Zenotech Lab.",
    "full_name": "Zenotech Laboratories Ltd",
    "name_url": "stocks-analysis/zenotech-lab",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "47.45",
    "chg": 0.72,
    "chgp": "1.54%",
    "dir": 1,
    "prev_price": "46.73",
    "mcapval": "289.59 Cr",
    "mcap": "Micro Cap",
    "scripcode": 532039,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE486F01012",
    "curr_date": "Jun 18",
    "curr_time": "",
    "bse_nse_vol": "8.01 k",
    "exc_status": "Active",
    "traded_date": "Jun 18, 2026",
    "traded_date_str": "2026 06 18",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://marketsmojo.motilaloswaluat.com/MOSL-Landingstocks-analysis/zenotech-lab-683231-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [],
    "total": 98,
    "sid": "683231",
    "stock_news_url": "https://marketsmojo.motilaloswaluat.com/news/zenotech-laboratories-683231"
  },
  "announcements": [
    {
      "caption": "Compliances-Reg.24(A)-Annual Secretarial Compliance",
      "datetime": "27-May-2026",
      "details": "Submission of Annual Secretarial Compliance Report for the financial year 2025-26",
      "source": "BSE"
    },
    {
      "caption": "Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A",
      "datetime": "28-Apr-2026",
      "details": "<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Zenotech Laboratories Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L27100TG1989PLC010122</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>Nil</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Abdul Gafoor Mohammad <br/> Designation: Company Secretary and Compliance Officer <br/> EmailId: abdul.gafoor@zenotech.co.in</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Poly KV <br/> Designation: Chief Financial Officer <br/> EmailId: polykv@zenotech.co.in</div> </div> <div> <br/> Date: 28/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Considering And Approving Audited Standalone Financial Results Of The Company For The Quarter And Financial Year Ended March 31 2026.",
      "datetime": "23-Apr-2026",
      "details": "Zenotech Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/04/2026 inter alia to consider and approve Audited Standalone Financial Results for the quarter and financial year ended March 31 2026.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "",
      "data": [
        {
          "txt": "Zenotech Laboratories Ltd has announced <strong>17:22</strong> rights issue, ex-date: 01 Jun 17",
          "dt": "2017-06-01",
          "middle_text": "Rights Issue"
        }
      ]
    }
  ]
}

News and Views

No Recent News for the Company

View All News